Ascendis Pharma A/S

NasdaqGS:ASND Stock Report

Market Cap: US$7.4b

Ascendis Pharma Valuation

Is ASND undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ASND when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ASND ($124.38) is trading below our estimate of fair value ($636.49)

Significantly Below Fair Value: ASND is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ASND?

Key metric: As ASND is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ASND. This is calculated by dividing ASND's market cap by their current revenue.
What is ASND's PS Ratio?
PS Ratio21.5x
Sales€327.43m
Market Cap€7.06b

Price to Sales Ratio vs Peers

How does ASND's PS Ratio compare to its peers?

The above table shows the PS ratio for ASND vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average20.2x
ACLX Arcellx
30.3x22.5%US$4.7b
TGTX TG Therapeutics
16.9x34.7%US$4.4b
LEGN Legend Biotech
14.2x35.5%US$7.0b
GBT Global Blood Therapeutics
19.7x32.5%US$4.6b
ASND Ascendis Pharma
21.5x41.9%US$7.4b

Price-To-Sales vs Peers: ASND is expensive based on its Price-To-Sales Ratio (21.5x) compared to the peer average (20.4x).

Price to Sales Ratio vs Industry

How does ASND's PS Ratio compare vs other companies in the US Biotechs Industry?

131 CompaniesPrice / SalesEstimated GrowthMarket Cap
GILD Gilead Sciences
3.9x2.4%US$109.25b
BIIB Biogen
2.4x1.3%US$22.65b
MRNA Moderna
2.8x7.2%US$14.35b
INCY Incyte
3.4x8.9%US$13.59b
ASND 21.5xIndustry Avg. 10.1xNo. of Companies131PS01632486480+
131 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: ASND is expensive based on its Price-To-Sales Ratio (21.5x) compared to the US Biotechs industry average (10.3x).

Price to Sales Ratio vs Fair Ratio

What is ASND's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ASND PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio21.5x
Fair PS Ratio20.9x

Price-To-Sales vs Fair Ratio: ASND is expensive based on its Price-To-Sales Ratio (21.5x) compared to the estimated Fair Price-To-Sales Ratio (20.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ASND forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$124.38
US$191.58
+54.0%
16.5%US$288.39US$152.68n/a14
Nov ’25US$125.28
US$195.74
+56.2%
15.4%US$287.71US$160.71n/a14
Oct ’25US$146.60
US$194.08
+32.4%
15.7%US$287.75US$156.24n/a13
Sep ’25US$138.45
US$194.08
+40.2%
14.8%US$279.11US$165.90n/a12
Aug ’25US$136.53
US$181.72
+33.1%
15.2%US$260.37US$140.23n/a12
Jul ’25US$133.98
US$183.29
+36.8%
16.3%US$262.96US$138.32n/a13
Jun ’25US$135.10
US$183.44
+35.8%
17.0%US$265.67US$139.74n/a13
May ’25US$141.01
US$177.33
+25.8%
19.3%US$259.53US$112.97n/a12
Apr ’25US$151.98
US$179.28
+18.0%
19.3%US$259.97US$115.56n/a12
Mar ’25US$152.47
US$172.80
+13.3%
14.3%US$226.19US$117.22n/a12
Feb ’25US$141.63
US$163.23
+15.3%
13.9%US$204.75US$117.59n/a12
Jan ’25US$125.95
US$149.82
+19.0%
12.9%US$202.25US$119.61n/a12
Dec ’24US$104.05
US$143.50
+37.9%
16.7%US$200.02US$112.41n/a12
Nov ’24US$90.79
US$141.57
+55.9%
16.9%US$192.33US$109.24US$125.2812
Oct ’24US$93.64
US$141.51
+51.1%
17.7%US$191.63US$109.89US$146.6011
Sep ’24US$98.27
US$135.46
+37.8%
21.6%US$185.38US$89.11US$138.4512
Aug ’24US$91.62
US$137.41
+50.0%
21.9%US$188.92US$89.43US$136.5312
Jul ’24US$89.25
US$136.41
+52.8%
22.0%US$187.14US$88.54US$133.9812
Jun ’24US$87.96
US$133.45
+51.7%
20.9%US$181.64US$87.29US$135.1013
May ’24US$86.74
US$137.14
+58.1%
21.7%US$193.85US$89.00US$141.0113
Apr ’24US$107.22
US$155.85
+45.4%
14.0%US$194.53US$108.68US$151.9814
Mar ’24US$113.21
US$154.33
+36.3%
12.5%US$180.06US$109.99US$152.4714
Feb ’24US$123.50
US$159.12
+28.8%
14.9%US$183.70US$95.60US$141.6314
Jan ’24US$122.13
US$160.65
+31.5%
15.5%US$192.00US$96.89US$125.9514
Dec ’23US$121.75
US$159.26
+30.8%
16.1%US$205.67US$93.41US$104.0515
Nov ’23US$116.71
US$150.85
+29.3%
17.9%US$196.79US$84.06US$90.7915

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

IQVIA Holdings

US$34.7b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$194.38

7D

-8.1%

1Y

-7.2%

Collegium Pharmaceutical

US$959.4m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$30.00

7D

-0.6%

1Y

15.5%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$55.10

7D

-7.9%

1Y

6.6%